实控人一致行动人再度发布减持计划，伟思医疗称脑机接口相关产品尚未实现规模化销售

Core Viewpoint - The recent share reduction plan by a significant shareholder of Weisi Medical raises concerns about the company's current performance and future prospects in the brain-computer interface sector, especially as the company has not yet achieved substantial revenue from its related products [1] Group 1: Shareholder Actions - The shareholder Nanjing Zhida Venture Capital Center plans to reduce its stake in Weisi Medical by up to 2,873,137 shares, which is no more than 3% of the total share capital [1] - Currently, Zhida Venture Capital holds 7.06% of Weisi Medical's shares [1] - This shareholder has previously cashed out over 52 million yuan in the second half of last year [1] Group 2: Business Performance - Weisi Medical's new products in the brain-computer interface field are still in the early stages of market cultivation as of the end of 2025 [1] - The company is primarily focusing on non-invasive technology, which significantly differs from the invasive brain-computer interfaces that are currently leading internationally [1] - The related products have not yet achieved large-scale sales, contributing only a limited amount to the overall revenue [1]